Annovis is attempting to lessen α-synuclein-induced pathogenesis by reducing the synthesis of the α-synuclein protein.
PNT article: First Patients Dosed in Clinical Trial Investigating ANVS401 as Treatment for Parkinson’s and Alzheimer’s
parkinsonsnewstoday.com/202...
Trial Record: Posiphen Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients
clinicaltrials.gov/ct2/show...
SoPD blog post (background info): Disney’s “Attack of the synucleozid from Jupiter”
scienceofparkinsons.com/202...
Posiphen (ANVS401) mode of action:
Posiphen is an orally available small molecule drug that inhibits the translation of α-synuclein, by increasing the affinity of Iron Regulatory Protein-1 (IRP1) to the Iron-Response Element (IRE) of the SNCA gene's messenger RNA (mRNA). This represses translation by preventing the association of the mRNA with the ribosome.
“Annovis Bio delivers candor on its Parkinson’s study, even if it doesn’t inspire much confidence”
Trehalose as a promising therapeutic candidate for the treatment of Parkinson's disease - 2019
Parkinson's Disease: emerging treatment target, the NLRP inflammasome. 
Phase 3 trial of buntanetap for early-stage Parkinson’s nears end
